RBC Capital Sticks to Their Hold Rating for PTC Therapeutics (PTCT)

RBC Capital analyst Brian Abrahams maintained a Hold rating on PTC Therapeutics (PTCT – Research Report) yesterday and set a price target of $29.00. The company’s shares closed yesterday at $25.49.

According to TipRanks, Abrahams is a 4-star analyst with an average return of 6.5% and a 46.98% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Regeneron, SAGE Therapeutics, and Biogen.

The word on The Street in general, suggests a Hold analyst consensus rating for PTC Therapeutics with a $29.22 average price target, implying a 14.63% upside from current levels. In a report released today, Barclays also maintained a Hold rating on the stock with a $25.00 price target.

The company has a one-year high of $59.84 and a one-year low of $17.53. Currently, PTC Therapeutics has an average volume of 906K.

Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PTCT in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

PTC Therapeutics (PTCT) Company Description:

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.